The immunogenetics of primary biliary cirrhosis: A comprehensive review

Journal of Autoimmunity

Volumn 64, Issue , 2015, Pages 42-52

  Webb, G J ^a   Siminovitch, K A ^b   Hirschfield, G M ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Animal models; CD4+ T cell; Genome wide association study; HLA; Immunochip; Regulatory T cell

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; IKZF3 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; INTERLEUKIN 7 RECEPTOR; INTERLEUKIN 7 RECEPTOR ALPHA; PROTEIN; STAT4 PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; HLA ANTIGEN;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CHOLANGITIS; CHROMOSOME 6; EPIGENETICS; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HERITABILITY; HLA SYSTEM; HUMAN; IMMUNOGENETICS; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; NONHUMAN; PHENOTYPE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE ACTIVATION; TH1 CELL; UBIQUITINATION; ANIMAL; EPISTASIS; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETIC SELECTION; GENETIC VARIATION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; IMMUNOLOGY; LIVER CIRRHOSIS, BILIARY; METABOLISM; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; B-LYMPHOCYTE SUBSETS; EPIGENESIS, GENETIC; EPISTASIS, GENETIC; GENE EXPRESSION REGULATION; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HLA ANTIGENS; HUMANS; IMMUNOGENETICS; LIVER CIRRHOSIS, BILIARY; PHENOTYPE; SELECTION, GENETIC; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS;

EID: 84946472960     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2015.07.004     Document Type: Review

References (114)

1. Hirschfield G.M., Gershwin M.E. The immunobiology and pathophysiology of primary biliary cirrhosis. Annu. Rev. Pathol. Mech. Dis. 2013, 8(1):303-330.
2. Boonstra K., Beuers U., Ponsioen C.Y. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: A systematic review. J. Hepatol. 2012, 56(5):1181-1188.
3. Watt F.E., James O.F.W., Jones D.E.J. Patterns of autoimmunity in primary biliary cirrhosis patients and their families: a population-based cohort study. QJM 2004, 97(7):397-406.
4. Somers E.C., et al. Are individuals with an autoimmune disease at higher risk of a second autoimmune disorder?. Am. J. Epidemiol. 2009, 169(6):749-755.
5. Gershwin M.E., et al. Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J. Immunol. 1987, 138(10):3525-3531.
6. Bogdanos D.P., Komorowski L. Disease-specific autoantibodies in primary biliary cirrhosis. Clin. Chim. Acta 2011, 412(7-8):502-512.
7. Migliaccio C., et al. Monoclonal antibodies to mitochondrial E2 components define autoepitopes in primary biliary cirrhosis. J. Immunol. Baltim. Md. 1950 1998, 161(10):5157-5163.
8. Matsumura S., et al. Contribution to antimitochondrial antibody production: cleavage of pyruvate dehydrogenase complex-E2 by apoptosis-related proteases. Hepatology 2002, 35(1):14-22.
9. Tsuneyama K., et al. Human combinatorial autoantibodies and mouse monoclonal antibodies to PDC-E2 produce abnormal apical staining of salivary glands in patients with coexistent primary biliary cirrhosis and Sjogren's syndrome. Hepatology 1994, 20(4 Pt 1):893-898.
10. Hashimoto E., et al. Immunohistochemical characterization of hepatic lymphocytes in primary biliary cirrhosis in comparison with primary sclerosing cholangitis and autoimmune chronic active hepatitis. Mayo Clin. Proc. 1993, 68(11):1049-1055.
11. Shimoda S., et al. Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis. J. Clin. Invest. 1998, 102(10):1831-1840.
12. Kita H., et al. Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis. J. Clin. Invest. 2002, 109(9):1231-1240.
13. Baba N., et al. Gene expression profiling in biliary epithelial cells of primary biliary cirrhosis using laser capture microdissection and cDNA microarray. Transl. Res. 2006, 148(3):103-113.
14. Van den Oord J.J., Sciot R., Desmet V.J. Expression of MHC products by normal and abnormal bile duct epithelium. J. Hepatol. 1986, 3(3):310-317.
15. Barbatis C., et al. Immunocytochemical analysis of HLA class II (DR) antigens in liver disease in man. J. Clin. Pathol. 1987, 40(8):879-884.
16. Nagano T., et al. Cytokine profile in the liver of primary biliary cirrhosis. J. Clin. Immunol. 1999, 19(6):422-427.
17. Harada K., et al. In situ nucleic acid hybridization of cytokines in primary biliary cirrhosis: predominance of the Th1 subset. Hepatology 1997, 25(4):791-796.
18. Fracchia M., et al. Serum interferon gamma in primary biliary cirrhosis: effect of ursodeoxycholic acid and prednisone therapy alone and in combination. Eur. J. Gastroenterol. Hepatol. 2000, 12(4):463-468.
19. Yamano T., et al. Serum interferon-gamma-inducing factor/IL-18 levels in primary biliary cirrhosis. Clin. Exp. Immunol. 2000, 122(2):227-231.
20. Yang C.-Y., et al. IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy. Hepatology 2014, 59:1944-1953.
21. Rong G., et al. Imbalance between T helper type 17 and T regulatory cells in patients with primary biliary cirrhosis: the serum cytokine profile and peripheral cell population. Clin. Exp. Immunol. 2009, 156(2):217-225.
22. Daniels J.A., et al. Immunostaining of plasma cells in primary biliary cirrhosis. Am. J. Clin. Pathol. 2009, 131(2):243-249.
23. Zhang W., et al. Deficiency in regulatory T cells results in development of antimitochondrial antibodies and autoimmune cholangitis. Hepatology 2008, 49(2):545-552.
24. Oertelt S., et al. Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice. J. Immunol. Baltim. Md. 1950 2006, 177(3):1655-1660.
25. Wakabayashi K., et al. IL-2 receptor α-/- mice and the development of primary biliary cirrhosis. Hepatology 2006, 44(5):1240-1249.
26. Salas J.T., et al. Ae2a,b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis. Gastroenterology 2008, 134(5):1482-1493.
27. Irie J., et al. NOD.c3c4 congenic mice develop autoimmune biliary disease that serologically and pathogenetically models human primary biliary cirrhosis. J. Exp. Med. 2006, 203(5):1209-1219.
28. Mattner J., et al. Liver autoimmunity triggered by microbial activation of natural killer T cells. Cell Host Microbe 2008, 3(5):304-315.
29. Wakabayashi K., et al. Induction of autoimmune cholangitis in non-obese diabetic (NOD).1101 mice following a chemical xenobiotic immunization. Clin. Exp. Immunol. 2009, 155(3):577-586.
30. Yao Y., et al. Distinct from its canonical effects, deletion of IL-12p40 induces cholangitis and fibrosis in interleukin-2Rα-/- mice. J. Autoimmun. 2014, 51(c):99-108.
31. Tsuda M., et al. Deletion of interleukin (IL)-12p35 induces liver fibrosis in dominant-negative TGFbeta receptor type II mice. Hepatology 2013, 57(2):806-816.
32. Yoshida K., et al. Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor beta receptor type II mice. Hepatology 2009, 50(5):1494-1500.
33. Selmi C., et al. Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. YGAST 2004, 127(2):485-492.
34. Lazaridis K.N., et al. Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology 2007, 46(3):785-792.
35. Mantaka A., et al. Primary biliary cirrhosis in a genetically homogeneous population: disease associations and familial occurrence rates. BMC Gastroenterol. 2012, 12(1). 1-1.
36. Selmi C., et al. Genes and (auto)immunity in primary biliary cirrhosis. Genes. Immun. 2005, 6(7):543-556.
37. Jones D.E., et al. Familial primary biliary cirrhosis reassessed: a geographically-based population study. J. Hepatol. 1999, 30(3):402-407.
38. Gershwin M.E., et al. Risk factors and comorbidities in primary biliary cirrhosis: A controlled interview-based study of 1032 patients. Hepatology 2005, 42(5):1194-1202.
39. Arbour L., et al. Characteristics of primary biliary cirrhosis in British Columbia's first nations population. Can. J. Gastroenterol. 2005, 19(5):305-310.
40. Delgado J., et al. The epidemiology of primary biliary cirrhosis in southern Israel. Israel Med. Assoc. J. IMAJ 2005, 7(11):717-721.
41. Tsuji K., et al. Familial primary biliary cirrhosis in Hiroshima. J. Autoimmun. 1999, 13(1):171-178.
42. Parkes M., et al. Genetic insights into common pathways and complex relationships among immune-mediated diseases. Nat. Rev. Genet. 2013, 14(9):661-673.
43. Lessard C.J., et al. The genomics of autoimmune disease in the era of genome-wide association studies and beyond. Autoimmun. Rev. 2012, 11(4):267-275.
44. Manolio T.A., et al. Finding the missing heritability of complex diseases. Nature 2009, 461(7265):747-753.
45. Hirschfield G.M., et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 Variants. N. Engl. J. Med. 2009, 360(24):2544-2555.
46. Liu X., et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis 2010, 42(8):658-660. Nature Publishing Group.
47. Mells G.F., et al. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat. Genet. 2011, 43(4):329-332.
48. Nakamura M., et al. Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population. Am. J. Hum. Genet. 2012, 91(4):721-728.
49. Cordell H.J., et al. International genome-wide meta-analysis in primary biliary cirrhosis discovers six new risk loci and highlights the role of JAK-STAT/IL12/IL27 signaling and cytokine-cytokine pathways in disease etiology. Nat. Commun. 2015, 1-13. (in press).
50. Hirschfield G.M., et al. Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis 2010, 42(8):655-657. Nature Publishing Group.
51. Juran B.D., et al. Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. Hum. Mol. Genet. 2012, 21(23):5209-5221.
52. Liu J.Z., et al. Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis 2012, 44(10):1137-1141. Nature Publishing Group.
53. Ercilla G., et al. Primary biliary cirrhosis associated with HLA-DRw3. Tissue Antigens 1979, 14(5):449-452.
54. Manns M.P., et al. HLA DRw8 and complement C4 deficiency as risk factors in primary biliary cirrhosis. Gastroenterology 1991, 101(5):1367-1373.
55. Invernizzi P., et al. Human leukocyte antigen polymorphisms in italian primary biliary cirrhosis: a multicenter study of 664 patients and 1992 healthy controls. Hepatology 2008, 48(6):1906-1912.
56. Chow I.T., et al. Differential binding of pyruvate dehydrogenase complex-E2 epitopes by DRB1*08:01 and DRB1*11:01 is predicted by their structural motifs and correlates with disease risk. J. Immunol. 2013, 190(9):4516-4524.
57. Ishizaki M., et al. Involvement of tyrosine kinase-2 in both the IL-12/Th1 and IL-23/Th17 axes in vivo. J. Immunol. 2011, 187(1):181-189.
58. Chang H.-C., et al. Impaired development of human Th1 cells in patients with deficient expression of STAT4. Blood 2009, 113(23):5887-5890.
59. Yang Z., et al. Autoimmune diabetes is blocked in Stat4-deficient mice. J. Autoimmun. 2004, 22(3):191-200.
60. Vereecke L., Beyaert R., van Loo G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol. 2009, 30(8):383-391.
61. Strebovsky J., et al. Suppressor of cytokine signaling 1 (SOCS1) limits NFkappaB signaling by decreasing p65 stability within the cell nucleus. FASEB J. 2011, 25(3):863-874.
62. Good-Jacobson K.L., et al. CD80 expression on B cells regulates murine T follicular helper development, germinal center B cell survival, and plasma cell generation. J. Immunol. 2012, 188(9):4217-4225.
63. Peschon J.J., et al. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J. Exp. Med. 1994, 180(5):1955-1960.
64. Liston A., Enders A., Siggs O.M. Unravelling the association of partial T-cell immunodeficiency and immune dysregulation. Nat. Rev. Immunol. 2008, 8(7):545-558.
65. Liu W. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J. Exp. Med. 2006, 203(7):1701-1711.
66. Ma S., et al. Ikaros and Aiolos inhibit pre-B-cell proliferation by directly suppressing c-Myc expression. Mol. Cell. Biol. 2010, 30(17):4149-4158.
67. Sun J., et al. Lack of the transcriptional coactivator OBF-1 prevents the development of systemic lupus erythematosus-like phenotypes in Aiolos mutant mice. J. Immunol. 2003, 170(4):1699-1706.
68. Quintana F.J., et al. Aiolos promotes TH17 differentiation by directly silencing Il2 expression. Nat. Immunol. 2012, 13(8):770-777.
69. Katayama H., et al. Lnk prevents inflammatory CD8(+) T-cell proliferation and contributes to intestinal homeostasis. Eur. J. Immunol. 2014, 44(6):1622-1632.
70. Haynes N.M., et al. Role of CXCR5 and CCR7 in follicular Th cell positioning and appearance of a programmed cell death gene-1high germinal center-associated subpopulation. J. Immunol. 2007, 179(8):5099-5108.
71. Schubart D.B., et al. B-cell-specific coactivator OBF-1/OCA-B/Bob1 required for immune response and germinal centre formation. Nature 1996, 383(6600):538-542.
72. Kumpfel T., Hohlfeld R. Multiple sclerosis. TNFRSF1A, TRAPS and multiple sclerosis. Nat. Rev. Neurol. 2009, 5(10):528-529.
73. Meylan F., Richard A.C., Siegel R.M. TL1A and DR3, a TNF family ligand-receptor pair that promotes lymphocyte costimulation, mucosal hyperplasia, and autoimmune inflammation. Immunol. Rev. 2011, 244(1):188-196.
74. Green E.A., Flavell R.A. TRANCE-RANK, a new signal pathway involved in lymphocyte development and T cell activation. J. Exp. Med. 1999, 189(7):1017-1020.
75. Hayden M.S., Ghosh S. NF-kappaB, the first quarter-century: remarkable progress and outstanding questions. Genes. Dev. 2012, 26(3):203-234.
76. Sha W.C., et al. Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell 1995, 80(2):321-330.
77. Honda K., Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat. Rev. Immunol. 2006, 6(9):644-658.
78. Turcotte K., et al. Icsbp1/IRF-8 is required for innate and adaptive immune responses against intracellular pathogens. J. Immunol. 2007, 179(4):2467-2476.
79. Hieshima K., et al. Molecular cloning of a novel human CC chemokine liver and activation-regulated chemokine (LARC) expressed in liver. Chemotactic activity for lymphocytes and gene localization on chromosome 2. J. Biol. Chem. 1997, 272(9):5846-5853.
80. Affo S., et al. CCL20 mediates lipopolysaccharide induced liver injury and is a potential driver of inflammation and fibrosis in alcoholic hepatitis. Gut 2014, 63(11):1782-1792.
81. Oo Y.H., et al. CXCR3-dependent recruitment and CCR6-mediated positioning of Th-17 cells in the inflamed liver. J. Hepatol. 2012, 57(5):1044-1051.
82. Agarwal K., et al. CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis. J. Hepatol. 2000, 32(4):538-541.
83. Juran B.D., et al. Carriage of a tumor necrosis factor polymorphism amplifies the cytotoxic T-lymphocyte antigen 4 attributed risk of primary biliary cirrhosis: evidence for a gene-gene interaction. Hepatology 2010, 52(1):223-229.
84. Simpson T.R., Quezada S.A., Allison J.P. Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). Curr. Opin. Immunol. 2010, 22(3):326-332.
85. Tang, R., et al., The cumulative effects of known susceptibility variants to predict primary biliary cirrhosis risk. (2015) 1-6.
86. Juran B.D., Lazaridis K.N. Environmental factors in primary biliary cirrhosis. Semin. Liver Dis. 2014, 34(3):265-272.
87. Invernizzi P., et al. Frequency of monosomy X in women with primary biliary cirrhosis. Lancet 2004, 363(9408):533-535.
88. Invernizzi P., et al. X chromosome monosomy: a common mechanism for autoimmune diseases. J. Immunol. 2005, 175(1):575-578.
89. Jorgensen K.T., et al. Autoimmune diseases in women with Turner's syndrome. Arthritis Rheum. 2010, 62(3):658-666.
90. Lleo A., et al. Y chromosome loss in male patients with primary biliary cirrhosis. J. Autoimmun. 2013, 41:87-91.
91. Miozzo M., et al. Preferential X chromosome loss but random inactivation characterize primary biliary cirrhosis. Hepatology 2007, 46(2):456-462.
92. Lleo A., et al. Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis. Hepatology 2012, 55(1):153-160.
93. - anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis. Hepatology 2012, 56(2):687-697.
94. Padgett K.A., et al. Primary biliary cirrhosis is associated with altered hepatic microRNA expression. J. Autoimmun. 2009, 32(3-4):246-253.
95. Umemura T., et al. Human leukocyte antigen class II molecules confer both susceptibility and progression in Japanese patients with primary biliary cirrhosis. Hepatology 2012, 55(2):506-511.
96. Pulickal A.S., et al. Biliary cirrhosis in a child with inherited interleukin-12 deficiency. J. Trop. Pediatr. 2008, 54(4):269-271.
97. Döffinger R., et al. Autoantibodies to interferon-gamma in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunity. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2004, 38(1):e10-4.
98. Dumoulin F.L., et al. Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis. Biomed. Pharmacother. 1999, 53(5-6):242-254.
99. Carbone M., et al. Calcineurin inhibitors and the IL12A locus influence risk of recurrent primary biliary cirrhosis after liver transplantation. Am. J. Transpl. 2013, 13(4):1110-1111.
100. Wang L., et al. CXCR5 +CD4 +T follicular helper cells participate in the pathogenesis of primary biliary cirrhosis. Hepatology 2015 Feb, 61(2):627-638. Epub 2015 Jan 5. 10.1002/hep.27306.
101. Webb G.J., Hirschfield G.M. Follicles, germinal centers, and immune mechanisms in primary biliary cirrhosis. Hepatology 2015, 61(2):424-427.
102. Kikuchi K., et al. Splenic lymph follicles generate immunoglobulin M-producing B cells in primary biliary cirrhosis. Hepatol Res. 2014 Oct, 44(10):E253-E256. 10.1111/hepr.12231.
103. Poupon R., et al. Genetic factors of susceptibility and of severity in primary biliary cirrhosis. J. Hepatol. 2008, 49(6):1038-1045.
104. Aiba Y., et al. Genetic polymorphisms in CTLA4 and SLC4A2 are differentially associated with the pathogenesis of primary biliary cirrhosis in Japanese patients. J. Gastroenterol. 2011, 46(10):1203-1212.
105. Hitomi Y., et al. Human primary biliary cirrhosis-susceptible allele of rs4979462 enhances TNFSF15 expression by binding NF-1. Hum Genet. 2015 Jul, 134(7):737-747. 10.1007/s00439-015-1556-3.
106. Hirschfield G.M., et al. P367 phase 2 study evaluating the efficacy and safety of ustekinumab in patients with primary biliary cirrhosis WHO had an inadequate response to whom it may concern: ursodeoxycholic acid. J. Hepatol. 2014, 60(1):S189-S190.
107. Kopp T., et al. Clinical improvement in psoriasis with specific targeting of interleukin-23. Nature 2015, 521(7551):222-226.
108. Dhirapong A., et al. Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis. Hepatology 2013, 57(2):708-715.
109. Dyson J.K., et al. Unmet clinical need in autoimmune liver diseases. J. Hepatol. 2014, 62(1):208-218.
110. Krzywinski M.I., et al. Circos: an information aesthetic for comparative genomics. Genome Res. 2009 Sep, 19(9):1639-1645. 10.1101/gr.092759.109.
111. Liu X., et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis 2010, 42(8):658-660. Nature Publishing Group. 10.1002/9780470015902.a0024406.
112. Mells G.F., Hirschfield G.M. Genetics of primary biliary cirrhosis. eLS 2013.
113. Invernizzi P., et al. Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis 2012, 13(6):461-468.
114. Zhao D.T., et al. Human leucocyte antigen alleles and haplotypes and their associations with antinuclear antibodies features in Chinese patients with primary biliary cirrhosis. Liver Int. 2014, 34(2):220-226.